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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Thai language. 
The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 104 JIA patients (45.2% systemic JIA, 10.6% oligoarticular, 9.6% RF negative polyarthritis, 
34.6% other categories) and 102 healthy children, were enrolled in one paediatric rheumatology centre. Notably, none of 
the enrolled JIA patients is affected with psoriatic arthritis or undifferentiated arthritis. The JAMAR components discrimi-
nated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory psychometric performances. 
In conclusion, the Thai version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use 
both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Thai parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthri-
tis (JIA). The JAMAR assesses the most relevant parent/
patient-reported outcomes in JIA, including overall well-
being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with ill-
ness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Thai language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from June 2015 to 
November 2015. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections.
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL.
A separate score for PhH and PsH (range 0–15) can be 
calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e. Spanish in South Ameri-
can countries), only the probe technique was performed. 
Reading comprehension and understanding of the translated 
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questionnaires were tested in a probe sample of ten JIA par-
ents and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption (mean and standard deviation [SD] equiva-
lence); the second Likert assumption or equal items-scale 
correlations (Pearson r all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Thai parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Thai JAMAR was fully cross-culturally adapted with 
two forward and two backward translations. The concord-
ance rate between the original standard English version 
of the JAMAR and the two back-translations was 68.3% 
(84/123 lines) for the parent version and 70.8% (85/120 
lines) for the child version.
Of the 123 lines in the patient version of the JAMAR, 
119 (97%) lines were understood by at least 80% of the 
ten parents tested (median = 100%; range 60–100%). Of 
the 120 lines in the patient version of the JAMAR, 116 
(97%) lines were understood by at least 80% of the children 
(median = 100%; range 40–100%). Lines 47, 60, 111, and 
114 of the parent version of the JAMAR and lines 45, 58, 
108, and 111 of the child version of the JAMAR were modi-
fied considering to parents’ and patients’ suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 104 JIA patients and 102 healthy children (total of 
206 subjects), were enrolled at the paediatric rheumatology 
clinic in Ramathibodi Hospital.
In the 104 JIA subjects, the JIA categories were 45.2% 
with systemic JIA, 10.6% with oligoarthritis, 9.6% with RF 
negative polyarthritis, 10.6% with RF positive polyarthritis 
and 24.0% with enthesitis related arthritis. Notably, none of 
the enrolled JIA patients is affected with psoriatic arthritis 
or undifferentiated arthritis (Table 1).
A total of 188/206 (91.3%) subjects had the parent ver-
sion of the JAMAR completed by a parent (87 from parents 
of JIA patients and 101 from parents of healthy children). 
The JAMAR was completed by 168/188 (89.4%) mothers 
and 20/188 (10.6%) fathers. The child version of the JAMAR 
was completed by 141/206 (68.4%) children age 5.1 or older. 
Also patients younger than 7 year old, capable to assess their 
personal condition and able to read and write, were asked to 
fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median  (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did 
not allow to skip answers and input of null values. The 
response pattern for both PF and HRQoL was positively 
skewed toward normal functional ability and normal 
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HRQoL. A reduced number of response choices were used 
for the different HRQoL items except for items 2, 3 and 4, 
whereas a reduced number of response choices was used 
for all the PF items except for items 3 and 5. The mean 
and SD of the items within a scale were roughly equivalent 
for the PF and for the HRQoL items (data not shown). The 
median number of items marked as not applicable was 0% 
(0–1%) for the PF and 0% (0–1%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 94.3% (88.5–96.6%) for the PF 
items, 80.5% (77.0–90.8%) for the HRQoL PhH items, and 
87.4% (86.2–94.3%) for the HRQoL PsH items. The median 
ceiling effect was 0% (0–1.1%) for the PF items, 1.1% 
(0–2.3%) for the HRQoL PhH items, and 0.0% (0–0.0%) for 
the HRQoL PsH items. The median floor effect was 69.0% 
for the pain VAS, 66.7% for the disease activity VAS and 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 87/188 Child N = 92/141
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 94.3% 94.6%
 HRQoL PhH 80.5% 89.1%
 HRQoL PsH 87.4% 89.1%
 Pain VAS 69.0% 69.6%
 Disease activity VAS 66.7% 67.4%
 Well-being VAS 56.3% 65.2%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 1.1% 0.0%
 HRQoL PsH 0.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item-scale correlation 67% for PF, 90% for HRQoL 87% for PF, 80% for HRQoL
Items with items-scale correlation ≥ 0.4 73% for PF, 70% for HRQoL 80% for PF, 80% for HRQoL
Cronbach’s alpha
 PF-LL 0.84 0.77
 PF-HW 0.76 0.85
 PF-US 0.60 0.74
 HRQoL-PhH 0.77 0.77
 HRQoL-PsH 0.65 0.73
Items with item-scale correlation lower than the Cronbach alpha 87% for PF, 90% for HRQoL 87% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.96 0.80
 HRQoL-PhH 0.95 0.57
 HRQoL-PsH 0.00 0.00
Spearman’s correlation with JIA core-set variables, median
 PF 0.4 0.4
 HRQoL PhH 0.6 0.6
 HRQoL PsH 0.2 0.2
 Pain VAS 0.4 0.4
 Disease activity VAS 0.4 0.5
 Well-being VAS 0.4 0.4
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56.3% for the well-being VAS. The median ceiling effect 
was 0% for the pain VAS, 0% for the disease activity VAS 
and 0% for the well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 67% of the 
PF items, with the exception of PF items 6, 10, 11, 14 and 
15, and for 90% of the HRQoL items, with the exception of 
HRQoL item 1.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 73% of items 
of the PF (except for PF items 10, 11, 14 and 15) and 70% of 
items of the HRQoL (except for HRQoL items 1, 7 and 9).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.84 for PF-LL, 0.76 for PF-HW, 0.60 
for PF-US. Cronbach’s alpha was 0.77 for HRQoL-PhH and 
0.65 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales 
of the questionnaires was lower than the Cronbach’s alpha 
except for the PF items 12 and 13, and for the HRQoL item 
4.
Test–retest reliability
Reliability was assessed in eight JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 8 days (8–8 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.96). The ICC for the HRQoL PhH 
showed an almost perfect reproducibility (ICC = 0.95) while 
the ICC for the HRQoL PsH showed a poor reproducibility 
(ICC = 0.0).
Convergent validity
The Spearman’s correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.3 to 
0.5 (median = 0.4). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.5, 
p < 0.001). The correlation of the PF total score with the ESR 
was not significant (p = 0.17). For the HRQoL, the median 
correlation of the PhH with the JIA core set of outcome 
variables ranged from 0.2 to 0.7 (median = 0.6), whereas for 
the PsH ranged from 0.04 to 0.4 (median = 0.2). The PhH 
showed the best correlation with the parent’s assessment 
of pain (r = 0.7, p < 0.001) and the PsH with the physician 
global assessment of well-being (r = 0.4, p = 0.0001). The 
median correlations between the pain VAS, the well-being 
VAS, and the disease activity VAS and the physician-centred 
and laboratory measures were 0.4 (0.3–0.5), 0.4 (0.2–0.5), 
0.4 (0.3–0.4), respectively.
Discussion
In this study, the Thai version of the JAMAR was fully cross-
culturally adapted from the original standard English version 
with two forward and two backward translations. According 
to the results of the validation analysis, the Thai parent and 
patient versions of the JAMAR possess satisfactory psycho-
metric properties. The disease-specific components of the 
questionnaire discriminated well between patients with JIA 
and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with some exceptions: four PF items (“open 
and close a tap or open a previously open jar”, “stretch out 
arms”, “bend head back” and “bite a sandwich or an apple”) 
and three HRQoL items (“have difficulty taking care”, “feel-
ing nervous or anxious” and “have difficulty concentrating 
or paying attention”) showed a lower items internal con-
sistency. Furthermore, the overall internal consistency for 
PF-US and for HRQoL-PsH subscales were questionable.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care. In conclusion, the Thai 
version of the JAMAR was found to have satisfactory psy-
chometric properties and it is, thus, a reliable and valid tool 
for the multidimensional assessment of children with JIA.
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